

# Seung U Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7017261/publications.pdf>

Version: 2024-02-01

363  
papers

11,645  
citations

36303

51  
h-index

49909

87  
g-index

373  
all docs

373  
docs citations

373  
times ranked

10852  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 358-369.e12.	4.4	17
2	Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514.	2.0	1
3	Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 956-958.e2.	4.4	13
4	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	4.4	12
5	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	2.9	37
6	Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	2.8	5
7	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <math>\geq 2,000\text{ IU/mL}</math>. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294.	0.4	8
8	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
9	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
10	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
11	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	3.7	6
12	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	3.7	1
13	Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00435.	2.5	21
14	Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 116, 114-121.	3.3	2
15	Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441.	2.6	1
16	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	2.0	7
17	Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2022, 65, 518-527.	6.3	12
18	Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1877-1880.e3.	4.4	2

#	ARTICLE	IF	CITATIONS
19	Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 241-247.	1.3	6
20	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	2.9	14
21	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 576-584.	1.6	1
22	Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B. <i>Liver International</i> , 2022, 42, 1017-1026.	3.9	9
23	Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101344.	2.9	15
24	Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1176-1185.e3.	0.8	10
25	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	3.7	4
26	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	2.6	8
27	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	3.7	8
28	Fibrotic burden during antiviral therapy for chronic hepatitis B, not <scp>ALT</scp> level, independently predicts liver cancer risk. <i>Liver International</i> , 2022, 42, 1902-1906.	3.9	1
29	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	2.3	26
30	The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. <i>Obesity Reviews</i> , 2022, 23, e13464.	6.5	8
31	Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101362.	2.9	3
32	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 425-472.	8.9	14
33	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
34	Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. <i>Hepatology</i> , 2021, 73, 466-466.	7.3	1
35	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	2.3	9
36	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	3.4	5
38	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	2.8	22
39	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	2.2	6
40	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	1.3	1
41	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	2.9	22
42	Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. <i>European Radiology</i> , 2021, 31, 4813-4823.	4.5	7
43	Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 4492-4503.	4.5	17
44	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	2.2	2
45	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	1.1	2
46	Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization. <i>Journal of Liver Cancer</i> , 2021, 21, 97-103.	1.1	0
47	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	2.0	6
48	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	8.9	19
49	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 257-269.	8.9	64
50	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	2.5	3
51	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	2.8	5
52	Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 1828.	3.7	7
53	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	2.9	11
54	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	3.7	2

#	ARTICLE	IF	CITATIONS
55	Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire. <i>Research in Nursing and Health</i> , 2021, 44, 844-853.	1.6	3
56	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	2.2	26
57	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401.	8.9	152
58	Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 402-412.	8.9	31
59	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	4.2	15
60	A qualitative study of self-management experiences in people with non-alcoholic fatty liver disease. <i>Nursing Open</i> , 2021, 8, 3135-3142.	2.4	9
61	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	2.0	4
62	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	7.3	28
63	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	2.0	8
64	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	4.2	18
65	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	3.7	8
66	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	2.0	15
67	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	4
68	Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2138-2147.e10.	4.4	237
69	Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927.	3.7	7
70	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	2.5	3
71	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	2.8	12
72	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	6
74	Authors'™ response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 574-574.	2.0	0
75	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	3.7	6
76	Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naïve hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 1328-1336.	4.2	12
77	Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4788-4806.	1.4	0
78	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	1.8	17
79	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	4.4	24
80	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	2.0	13
81	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	1.6	2
82	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	1.6	2
83	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	1.6	11
84	Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 5-7.	4.2	2
85	Genetically Engineered Mouse Models for Liver Cancer. <i>Cancers</i> , 2020, 12, 14.	3.7	23
86	MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy. <i>American Journal of Roentgenology</i> , 2020, 215, 1354-1362.	2.2	17
87	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	1.7	18
88	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	3.7	9
89	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.9	6
90	Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2020, 73, 988-989.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 913-914.	3.7	1
92	Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2020, 73, 1270-1271.	3.7	2
93	Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment" still an open issue. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 889-890.	3.7	1
94	A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	2.0	7
95	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32
96	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	2.3	3
97	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	3.7	21
98	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	2.0	6
99	Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020, Volume 15, 831-839.	2.3	8
100	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	2.0	7
101	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
102	Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2020, 158, 2310-2311.	1.3	2
103	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
104	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.8	19
105	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 855-862.	3.7	67
106	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	2.5	13
107	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743.	3.9	23
108	Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy. <i>Journal of Hepatology</i> , 2020, 73, 222-223.	3.7	2

#	ARTICLE	IF	CITATIONS
109	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.4	68
110	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	2.5	30
111	<p>Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	3.7	6
112	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	2.5	6
113	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	8.9	31
114	Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44.	8.9	20
115	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	2.9	1
116	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	2.9	19
117	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	2.9	20
118	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	1.7	3
119	Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune-tolerant phase authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1094-1095.	3.7	0
120	Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. <i>European Radiology</i> , 2019, 29, 1022-1031.	4.5	9
121	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 333-334.	3.7	2
122	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.5	15
123	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	2.8	25
124	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	1.5	13
125	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 275.	1.0	19
126	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	2.3	8

#	ARTICLE	IF	CITATIONS
127	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	4.4	17
128	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	2.6	8
129	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	3.9	29
130	Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 523-530.	3.0	19
131	The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 375.	2.4	9
132	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	2.4	9
133	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	3.7	37
134	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	3.7	8
135	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	2.5	7
136	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	3.7	131
137	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	1.7	32
138	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	3.3	20
139	Diagnostic Performance of Serum Asialo- $\alpha$ 1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 74, 341.	0.4	6
140	The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years. <i>Journal of Clinical Medicine</i> , 2019, 8, 2065.	2.4	11
141	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	2.5	17
142	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	3.3	4
143	Prediction of the varices needing treatment with noninvasive tests in patients with compensated advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 1071-1079.	3.9	33
144	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	4.4	59

#	ARTICLE	IF	CITATIONS
145	Fibrosisâ€matched outcomes between chronic hepatitis B patients with drugâ€induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	3.9	4
146	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	1.6	14
147	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	8.9	31
148	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	8.9	20
149	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	2.9	12
150	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	2.9	5
151	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212.	3.7	14
152	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	3.9	16
153	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virusâ€related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510.	2.8	24
154	Asiaâ€Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017â€Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
155	The Asiaâ€Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017â€Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
156	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	3.9	22
157	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	5.0	7
158	Pharmacologic Treatment Using Non-Hypoglycemic Agents for Nonalcoholic Fatty Liver Disease. <i>Journal of Korean Diabetes</i> , 2018, 19, 97.	0.3	1
159	IDDF2018-ABS-0028â€...Risk assessment in patients treated with tace due to recurred hepatocellular carcinoma after curative resection. , 2018, , .		0
160	IDDF2018-ABS-0027â€...Influence of hepatic steatosis on the treatment outcomes of entecavir and tenofovir in patients with chronic hepatitis B. , 2018, , .		0
161	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478.	2.3	88
162	Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 300-312.	3.7	37

#	ARTICLE	IF	CITATIONS
163	Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 367-369.	8.9	4
164	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200.	2.9	8
165	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	2.9	8
166	Clinical Implications of Shear Wave Elastography in Patients with Chronic Hepatitis B. <i>Journal of Clinical Ultrasound</i> , 2018, 3, 45-49.	0.0	0
167	Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. <i>Acta Radiologica</i> , 2017, 58, 131-139.	1.1	32
168	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 208-214.	2.8	2
169	Comparison of treatment outcomes between balloon-occluded retrograde transvenous obliteration and transjugular intrahepatic portosystemic shunt for gastric variceal bleeding hemostasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1487-1494.	2.8	38
170	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.8	49
171	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276.	4.2	23
172	Bariatric Arterial Embolization with Non-spherical Polyvinyl Alcohol Particles for Ghrelin Suppression in a Swine Model. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 744-749.	2.0	17
173	Validation of PAGE model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	3.9	37
174	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	2.3	18
175	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	3.7	759
176	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.8	15
177	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299.	4.2	8
178	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.4	42
179	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	3.9	37
180	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 23-31.	3.4	55

#	ARTICLE	IF	CITATIONS
181	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086.	2.8	18
182	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	2.8	37
183	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. <i>Journal of Viral Hepatitis</i> , 2017, 24, 141-147.	2.0	23
184	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	2.8	36
185	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	5.0	5
186	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , 2017, 8, 113213-113224.	1.8	24
187	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 828-834.	2.9	24
188	Radiologic Evaluation of Non-Alcoholic Fatty Liver Disease in Diabetic Patient. <i>Journal of Korean Diabetes</i> , 2017, 18, 88.	0.3	1
189	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	1.8	22
190	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	1.8	7
191	Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 48-57.	2.2	5
192	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	2.9	5
193	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15678-e15678.	1.6	0
194	Can Magnetic Resonance Elastography Fill a Niche in the Market for Noninvasive Assessment of Liver Fibrosis?. <i>Gut and Liver</i> , 2017, 11, 321-322.	2.9	0
195	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	2.2	31
196	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	2.5	7
197	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	2.5	62
198	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	1.0	14

#	ARTICLE	IF	CITATIONS
199	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 676-685.	2.2	1
200	Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2985.	1.0	23
201	Reply to "prognostic model for patients receiving arterial embolization for hepatocellular carcinoma: issues to consider". <i>Liver International</i> , 2016, 36, 312-312.	3.9	0
202	Reply. <i>Hepatology</i> , 2016, 63, 672-673.	7.3	0
203	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034.	5.0	8
204	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	1.0	28
205	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	2.8	21
206	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	1.8	6
207	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	2.8	7
208	Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30.	3.9	29
209	Cryoablation of Hepatocellular Carcinoma with High-Risk for Percutaneous Ablation: Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1447-1454.	2.0	28
210	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786.	7.3	261
211	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	3.9	76
212	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	4.4	32
213	Prognostic Significance of <sup>18</sup> F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 509-516.	5.0	42
214	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	1.5	14
215	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	5.1	78
216	Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. <i>Digestive Diseases and Sciences</i> , 2016, 61, 507-516.	2.3	3

#	ARTICLE	IF	CITATIONS
217	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	1.5	68
218	Knockdown of HIF-1 $\alpha$ and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 85-95.	4.9	19
219	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	3.9	64
220	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	2.9	17
221	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	2.9	16
222	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	3.3	48
223	Reply to "Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue". <i>Journal of Hepatology</i> , 2015, 63, 1532.	3.7	0
224	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	2.8	28
225	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	7.3	97
226	Acoustic Radiation Force Impulse Measurement in Renal Transplantation. <i>Medicine (United States)</i> , 2015, 94, e1590.	1.0	45
227	Early $\alpha$ -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39.	3.7	24
228	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347.	2.0	22
229	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	2.5	32
230	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , 2015, 10, e0139227.	2.5	25
231	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	2.2	33
232	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348.	3.0	51
233	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.9	5
234	Reply to "The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?". <i>Journal of Hepatology</i> , 2015, 63, 281-282.	3.7	1

#	ARTICLE	IF	CITATIONS
235	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	3.7	148
236	Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. <i>Liver International</i> , 2015, 35, 1103-1115.	3.9	57
237	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	7.3	121
238	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	3.9	34
239	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
240	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	2.3	14
241	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	3.9	66
242	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	3.9	22
243	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). <i>Journal of Hepatology</i> , 2015, 63, 486-493.	3.7	264
244	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	2.3	34
245	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462.	3.9	18
246	Successful hemostasis of intractable rectal variceal bleeding using variceal embolization. <i>World Journal of Gastroenterology</i> , 2015, 21, 2558.	3.3	14
247	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776.	2.9	9
248	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.8	5
249	Can Non-invasive Fibrosis Assessment Predict Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2014, 64, 250.	0.4	0
250	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	2.5	25
251	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. <i>PLoS ONE</i> , 2014, 9, e99167.	2.5	24
252	Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 501-511.	3.0	11

#	ARTICLE	IF	CITATIONS
253	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	2.8	26
254	Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 313-321.	3.9	29
255	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir after stopping lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549.	3.9	10
256	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	7.3	37
257	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 272-278.	2.2	24
258	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	3.9	143
259	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	3.3	26
260	Inhibition of tumour angiogenesis and growth by small hairpin HIF-1 $\alpha$ and IL-8 in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	3.9	27
261	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017.	3.9	44
262	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	2.8	16
263	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	3.9	32
264	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.4	120
265	Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Long-term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078.	1.6	36
266	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	1.5	53
267	Congestive hepatopathy after Fontan operation and related factors assessed by transient elastography. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1498-1505.	0.8	50
268	Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795.	2.5	17
269	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	2.5	33
270	Silencing of Hypoxia-Inducible Factor-1 $\alpha$ Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304.	2.5	11

#	ARTICLE	IF	CITATIONS
271	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	8.9	10
272	Non-invasive prediction of forthcoming cirrhosis-related complications. <i>World Journal of Gastroenterology</i> , 2014, 20, 2613.	3.3	13
273	Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63.	2.9	64
274	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173.	2.3	33
275	Graft Function Measured by Transient Elastography in Living Donor Liver Transplantation: Preliminary. <i>Transplantation Proceedings</i> , 2013, 45, 3028-3031.	0.6	5
276	Clinical Application of Liver Stiffness Measurement Using Transient Elastography: A Surgical Perspective. <i>Digestion</i> , 2013, 88, 258-265.	2.3	19
277	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	2.8	71
278	Prognostic value of $\alpha$ -fetoprotein and des- $\gamma$ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5.	2.6	60
279	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	3.9	28
280	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	3.3	6
281	Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203.	2.3	2
282	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	2.2	42
283	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390.	2.8	57
284	Role of splenectomy in patients with hepatocellular carcinoma and hypersplenism. <i>ANZ Journal of Surgery</i> , 2013, 83, 865-870.	0.7	19
285	Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	3.9	14
286	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	7.0	38
287	Compensated heart failure does not always alleviate overestimation of liver stiffness by transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 385-387.	1.6	3
288	Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 514-515.	1.6	2

#	ARTICLE	IF	CITATIONS
289	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755.	2.0	11
290	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463.	2.0	22
291	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	2.2	4
292	The Use of Health Functional Foods in Gastrointestinal Cancer Patients. <i>Clinical Nutrition Research</i> , 2013, 2, 19.	1.2	5
293	Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. <i>PLoS ONE</i> , 2013, 8, e52720.	2.5	19
294	Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166.	2.5	26
295	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	2.5	20
296	Role of surgical resection for multiple hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2013, 19, 366.	3.3	36
297	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.2	5
298	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	2.5	11
299	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29.	8.9	13
300	Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 255.	8.9	3
301	Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. <i>World Journal of Gastroenterology</i> , 2013, 19, 1890.	3.3	67
302	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219.	3.3	51
303	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	2.9	12
304	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118.	2.8	11
305	Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607.	2.2	15
306	The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525.	2.2	49

#	ARTICLE	IF	CITATIONS
307	Acoustic radiation force impulse elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 215-216.	1.6	6
308	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	1.6	35
309	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	2.8	13
310	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	1.5	70
311	Can transient elastography be used for the management of chronic hepatitis B patients?. <i>Liver International</i> , 2012, 32, 528-530.	3.9	6
312	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	3.9	91
313	The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 556-563.	3.7	122
314	Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. <i>Hepatology International</i> , 2012, 6, 763-769.	4.2	22
315	Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Research and Therapy</i> , 2012, 14, R232.	3.5	45
316	Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation. <i>PLoS ONE</i> , 2012, 7, e32233.	2.5	49
317	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	2.5	45
318	Revision and update on clinical practice guideline for liver cirrhosis. <i>The Korean Journal of Hepatology</i> , 2012, 18, 1.	1.5	120
319	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337.	2.2	16
320	Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318.	2.2	11
321	Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328.	2.2	11
322	Combined measurement of preoperative Î <sub>1</sub> -fetoprotein and desâ <sub>1</sub> -carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341.	5.1	35
323	Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691.	2.3	90
324	Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136.	2.8	53

#	ARTICLE	IF	CITATIONS
325	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	2.8	30
326	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1343-1350.	3.7	83
327	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	2.8	29
328	Transient elastography in real practice: A time for action?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1134-1135.	2.8	0
329	Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676.	2.5	84
330	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	2.5	64
331	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930.	2.5	242
332	Clinical applications of transient elastography. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 163.	8.9	93
333	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	2.8	59
334	Gastroduodenal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.8	42
335	Acoustic radiation force impulse elastography is useful to exclude nonliver-related ascites. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1080-1081.	1.6	1
336	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	1.0	20
337	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 171-178.	2.8	42
338	Noninvasive assessment of liver fibrosis: The gap between ideal and real. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 937-939.	2.8	6
339	Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 598-607.	1.7	28
340	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	7.3	329
341	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	1.9	20
342	Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. <i>Anticancer Research</i> , 2011, 31, 4641-6.	1.1	21

#	ARTICLE	IF	CITATIONS
343	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	2.2	94
344	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680.	4.2	42
345	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811.	1.8	15
346	What are "true normal" liver stiffness values using FibroScan <sup>®</sup> : a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	3.9	76
347	Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 498-505.	3.7	47
348	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128.	2.8	37
349	Non-invasive assessment of liver fibrosis: Time to move from cross-sectional studies to longitudinal ones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1472-1473.	2.8	12
350	Response Rates to Medical Treatments and Long-term Clinical Outcomes of Nonsurgical Patients With Intestinal Behçet Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e116-e122.	2.2	34
351	Transient elastography in chronic hepatitis B: An Asian perspective. <i>World Journal of Gastroenterology</i> , 2010, 16, 5173.	3.3	30
352	The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. <i>Hepato-Gastroenterology</i> , 2010, 57, 832-8.	0.5	7
353	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	2.3	122
354	Liver stiffness measurement using FibroScan <sup>®</sup> is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815.	3.9	51
355	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766.	3.9	19
356	Liver Stiffness Measurement in Combination With Noninvasive Markers for the Improved Diagnosis of B-viral Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 267-271.	2.2	66
357	A Case of Hepatocellular Carcinoma Within Hepatocellular Adenoma in a Non-Cirrhotic Male. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 147.	1.7	25
358	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan <sup>®</sup> ) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7.	4.2	77
359	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	2.5	67
360	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	2.8	36

#	ARTICLE	IF	CITATIONS
361	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298.	2.8	8
362	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 923-926.	1.6	16
363	Regulation of <i>HK2</i> expression through alterations in CpG methylation of the <i>HK2</i> promoter during progression of hepatocellular carcinoma. <i>Oncotarget</i> , 0, 7, 41798-41810.	1.8	43